Taken together, it remains uncertain what clinical effect, if any, that differences in circulating TNFα and CRP may actually exert between AATD patients ‘on’ versus ‘off’ augmentation therapy. The gene discussed is TNF; the disease is alpha 1-antitrypsin deficiency.